To be honest - I'm not too excited about the annual report. MV's comments that 2022 could be a 'transformative year' for IMM. That's what he said about 2021 too.
'Planning for AIPAC phase 3 has commenced with further updates in FY22' - so really does this mean approval is going to be at least another 3+ years?
And only 11/26 patients for the first cohort of the EAT COVID trial have been recruited? That is a joke
Ann: Appendix 4E & 2021 Full Year Statutory Accounts, page-2
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 29.3¢ | $1.323M | 4.421M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 111754 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 61590 | 3 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |